NCT00492505 2014-01-10
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma
National Cancer Institute (NCI)
Phase 2 Unknown
Clinical Trials
9 trialsNCT00538005 2014-01-10
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01222676 2013-08-12
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01324076 2011-05-13
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00811759 2010-10-07
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01182272 2010-08-16
Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00874874 2009-12-24
Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00541021 2009-12-15
Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00801385 2009-08-25
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 2 Unknown